Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors
- 31 March 2005
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 51 (3) , 275-281
- https://doi.org/10.1016/j.phrs.2004.09.006
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cellsBritish Journal of Pharmacology, 2000
- Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cellsBritish Journal of Pharmacology, 1998
- Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.Journal of Clinical Investigation, 1996
- Plasma and neurohypophyseal content of vasopressin in diabetes mellitusJournal of Clinical Endocrinology & Metabolism, 1996
- Characterization of an oxytoc-ininduced rise in [Ca2+]i in single human myometrium smooth muscle cellsCell Calcium, 1996
- Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cellsLife Sciences, 1995
- Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissuesLife Sciences, 1992
- Effects of a specific inhibitor of the vascular action of vasopressin in humans.Hypertension, 1984
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONSAnnals of the New York Academy of Sciences, 1949